3SBio Inc. (HKG:1530)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
20.86
-0.38 (-1.79%)
At close: Mar 13, 2026
Market Cap52.10B +238.8%
Revenue (ttm)9.94B +7.7%
Net Income2.58B +42.2%
EPS1.05 +40.7%
Shares Out2.50B
PE Ratio19.85
Forward PE6.98
Dividend0.25 (1.20%)
Ex-Dividend DateJul 21, 2025
Volume14,718,500
Average Volume21,405,183
Open20.88
Previous Close21.24
Day's Range20.56 - 21.32
52-Week Range8.95 - 36.80
Beta0.66
RSI41.70
Earnings DateMar 20, 2026

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 6,268
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1530
Full Company Profile

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY Financial Statements